In Association With

Breaking News for Australian Medical and Health Practitioners

The TGA Has Just Approved a New tDCS Device* for Chronic Pain, Post-Stroke Rehab & Depression.

Here’s How to Safely Implement it in Your Practice.

*Newronika HDC-Kit (ARTG 492186) 

In June 2025, the Therapeutic Goods Administration (TGA) authorised a specific transcranial Direct Current Stimulation (tDCS) device* for three key indications:

  • Chronic Pain (Somatic Pain, Headache and Migraine, Neuropathic Pain, Cancer Pain)
  • Post-Stroke Rehabilitaiton (Gait and Mobility, Upper Extremity Function, Dysphagia, Cognition, Sleep)
  • Depression (Treatment Resistant, Adolescent, Alzhiemer's Disease)

This landmark decision opens a new, evidence-based treatment avenue for Australian clinicians working with patients who have not found sufficient relief with conventional therapies.

However, navigating the science, selecting appropriate patients, and integrating this modality into a clinical workflow requires a clear and structured approach.

This focused 10-minute clinical briefing, presented by Dr. Nicholas Lucas (PhD), is specifically designed for busy healthcare professionals who need essential clinical insights without the time commitment of traditional hour-long presentations.

We understand that your time is your most valuable resource, which is why we've distilled the most critical information into this concise, high-impact format.

Dr. Lucas is a former executive editor for the International Journal of Osteopathic Medicine, and advisor to Sozo Brain Center, which has over 3,500 documented patient cases and has trained over 300+ doctors in neuromodulation across Europe and the USA.

This streamlined webinar will provide a comprehensive overview of the new TGA-approved tDCS modality in just 10 minutes of your valuable time.

Key learning objectives include:

The TGA-Approved* Clinical Device Framework:

A detailed analysis of the regulatory changes and the specific indications for which the Newronika HDC-Kit is now approved. The only device currently authorised for all three conditions.

Evidence-Based Protocols for At-Home Treatment:

Discover the research-validated protocols that have shown comparable outcomes for at-home and in-clinic use in select clinical trials and patient cohorts. This is a significant advantage compared to the daily visit requirements of other approved modalities like TMS.

Mechanism of Action & Safety Profile:

A clear, scientific breakdown of how tDCS modulates neural pathways, including a thorough review of established safety parameters and risk mitigation strategies. (as per Australian ARTG 492186 listing)

Practical Aspects of Clinical Integration:

A discussion of the steps for incorporating this modality, from patient assessment and consent to the measurement of functional outcomes.

Register now to secure your access to this time-sensitive 10-Minute Clinical Briefing

Enter Your Details For Immediate Access To This Rapid Training

Current Progress
Current Progress
Current Progress
PLEASE CONFIRM YOUR STATUS TO PROCEED
I am a registered health professional
Watch the Briefing
Important Legal Notice: Under Australian healthcare regulations, the comprehensive clinical information presented in this briefing can only be shared with registered healthcare professionals. This registration requirement allows us to provide you with the complete, unfiltered clinical data and implementation strategies that would be legally restricted if presented to the general public.

This content is for registered healthcare professionals only and is intended for educational purposes. Clinical decisions should align with TGA-approved use of the HDC Kit (ARTG 492186). Individual results may vary. This approach is approved for use under health professional supervision to reduce symptoms associated with chronic pain, after-stroke rehabilitation and depression.

Your privacy is assured. Strict anti-SPAM policy applies. We will send research-based information about neuromodulation.
Unsubscribe in one-click.

What you’ll learn When You attend this Briefing:
  • The science behind neuromodulation (tDCS) and its application
  • A review of recent systematic reviews and meta-analyses for Safety and Effectiveness
  • How to address conditions where traditional treatment has limited results
  • Functional Network Operating Neuromodulation by SOZO Brain Center 

Why This Training is Unique

Maximum Clinical Value in Minimum Time Investment

This is the first neuromodulation training of its kind in Australia, and the only one designed specifically for time-conscious healthcare professionals. Discover this advanced approach innovated in Cyprus, Austria, and the United States, and expand beyond current practice and into this new, evidence-based approach: all in just 10 minutes of your valuable time.

The Perfect Balance: Comprehensive clinical insights delivered with respect for your professional schedule.

presented by dr nicholas lucas

BSc, MHSc, MPainMed, GDClinEpi, PhD (Medicine), ACTL

Dr Lucas lectured neuroscience and pain medicine for 10 years and has published in the Clinical Journal of Pain, Journal of Clinical Epidemiology, Medicine Health Care Philosophy, Medical Research Methodology, BMC Musculoskeletal Disorders, and Experimental Brain Research.

He completed his PhD in the Faculty of Medicine, University of Sydney.